tirzepatide cardiovascular outcomes study 💉 In a large real-world study, was associated with a lower incidence of major vs semaglutide: 📊 Composite CV outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) ❤️ New-onset heart Cardiovascular outcomes of semaglutide and

There were some early reports when GLP-1s first hit the market that they could cause depression in some people

& Faller, D

One study showed that In patients with type 2 diabetes inadequately controlled by metformin, dulaglutide at doses of 3.0 mg and 4.5 mg demonstrated significant and dose-related reductions in body weight compared to the 1.5 mg dose

Common formulations include: BPC-157: 10 mg per vial in typical KLOW formulations TB-500: 10 mg per vial in typical KLOW formulations GHK-Cu: 50 mg per vial in typical KLOW formulations (highest proportion) KPV: 10 mg per vial in typical KLOW formulations Total blend: 80 mg combined peptide content Individual component research dosing: BPC-157 studies: 10 mcg/kg most common in rat models (range: 1-1000 mcg/kg) TB-500 studies: 1-10 mg/kg typical range in rodent research GHK-Cu studies: 0.01-100 nanomolar in cell culture

However, reactions tend to be milder than those seen with GHK-Cu or MOTS-C

This is one of the most searched questions about GLP-1 weight loss medications and the answer surprises many people